Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of ASK120067 with Rifampicin or Itraconazole in Healthy Subjects
NCT05631678Phase 1Completed
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of limertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 15 and Area Under the Curve at Day 15. Started Jun 2022; status: completed.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05631678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631678.